|
2023 Journal Article Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphomaGandhi, Maher K. and Keane, Colm (2023). Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphoma. Haematologica, 108 (12), 3195-3196. doi: 10.3324/haematol.2023.283392 |
|
2023 Conference Publication An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatmentLavie, D., Johnson, N., Borchmann, P., Herrera, A. F., Avigdor, A., Gasiorowski, R., Gregory, G., Keane, C., Vucinic, V., Bazargan, M., Herishanu, Y., Minuk, L., Tzoran, I., Andreadis, C., Armand, P., Kuruvilla, J., Zinzani, P. L., West, R. Marceau, Pillai, P., Marinello, P. and Timmerman, J. (2023). An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_263 |
|
2023 Conference Publication Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphomaTobin, J. W., Tsang, H., Patch, A., Keane, C., Law, S. C., Gunawardana, J., Blombery, P., Thompson, E. R., Sabdia, M. B., De Long, L. M., Nath, K., Kazakoff, S. H., Cheah, C., Amanuel, B., Cochrane, T., Butler, J., Johnston, A., Shanavas, M., Li, L., Shelton, V., Hershenfeld, S., Kridel, R., Seymour, J. F., MacManus, M. and Gandhi, M. K. (2023). Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_189 |
|
2023 Conference Publication T cell CD62L expression following nivolumab therapy is associated with response to rituximab‐nivolumab in treatment naïve follicular lymphoma: the 1st FLOR studyKoldej, R. M., Barraclough, A., Lee, S. T., Morgan, H., Holzwart, N., Koshy, M., Smith, C., Chong, G., Gilbertson, M., Keane, C., Ting, S., Churilov, L., Ritchie, D. S. and Hawkes, E. A. (2023). T cell CD62L expression following nivolumab therapy is associated with response to rituximab‐nivolumab in treatment naïve follicular lymphoma: the 1st FLOR study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_183 |
|
2023 Conference Publication Polatuzumab, Bendamustine & Rituximab Efficacy In Relapsed/refractory Trial‐ineligible Large B Cell Lymphoma Patients: An Australian Lymphoma Registry (LARDR) StudyShaw, B., Chung, E., Wellard, C., Yoo, E., Bennett, R., Birks, C., Johnston, A., Cheah, C., Hamad, N., Simpson, J., Barraclough, A., Ku, M., Viiala, N., Ratnasingam, S., Armytage, T., Cochrane, T., Chong, G., Lee, D., Manos, K., Keane, C., Wallwork, S., Opat, S. and Hawkes, E. (2023). Polatuzumab, Bendamustine & Rituximab Efficacy In Relapsed/refractory Trial‐ineligible Large B Cell Lymphoma Patients: An Australian Lymphoma Registry (LARDR) Study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3165_572 |
|
2023 Conference Publication Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapseSwain, F., Burgess, M., Kempe, S., Sabdia, M., Wight, J., Hawkes, E., Mutsando, H., Talaulikar, D., Merida de Long, L., Hawula, Z., Birch, S., Wyche, P., Gandhi, M. K. and Keane, C. (2023). Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_191 |
|
2023 Conference Publication Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B‐cell Lymphoma (DLBCL) & Follicular Lymphoma (FL). The phase I “RaDD” studyHawkes, E. A., Palmer, J., Chong, G., Lee, S., Keane, C., Shortt, J., Scott, A. M., Churilov, L., Macmanus, M., Smith, C., Barraclough, A., Khor, R. and Manos, K. (2023). Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B‐cell Lymphoma (DLBCL) & Follicular Lymphoma (FL). The phase I “RaDD” study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_448 |
|
2023 Journal Article Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemiaBurgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631 |
|
2023 Journal Article A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphomaGeorge, Hannah, Gunawardana, Jay, Keane, Colm, Hicks, Rod J. and Gandhi, Maher K. (2023). A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma. Internal Medicine Journal, 53 (7), 1105-1109. doi: 10.1111/imj.16078 |
|
2023 Journal Article Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryNguyen, James, Wellard, Cameron, Chung, Eliza, Cheah, Chan Y., Dickinson, Michael, Doo, Nicole Wong, Keane, Colm, Talaulikar, Dipti, Berkahn, Leanne, Morgan, Susan, Hamad, Nada, Cochrane, Tara, Johnston, Anna M., Forsyth, Cecily, Opat, Stephen, Barraclough, Allison, Mutsando, Howard, Ratnasingam, Sumita, Giri, Pratyush, Wood, Erica M., McQuilten, Zoe K. and Hawkes, Eliza A. (2023). Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry. European Journal of Haematology, 110 (4), 386-395. doi: 10.1111/ejh.13915 |
|
2023 Journal Article EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohortAgrawal, Prashasti, David, Kevin A., Chen, Zhengming, Sundaram, Suchitra, Kim, Seo-Hyun, Vaca, Ryan, Lin, Yong, Singer, Samuel, Malecek, Mary-Kate, Carter, Jordan, Zayac, Adam, Kim, Myung Sun, Reddy, Nishitha, Ney, Douglas, Habib, Alma, Strouse, Christopher, Graber, Jerome, Bachanova, Veronika, Salman, Sidra, Vendiola, Jean A., Hossain, Nasheed, Tsang, Mazie, Major, Ajay, Gandhi, Maher K., Keane, Colm, Bond, David A., Folstad, Matthew, Chang, Julie, Mier-Hicks, Angel ... Martin, Peter (2023). EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leukemia and Lymphoma, 64 (5), 1026-1034. doi: 10.1080/10428194.2023.2191152 |
|
2023 Journal Article Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP studyManos, Kate, Chong, Geoffrey, Keane, Colm, Lee, Sze-Ting, Smith, Charmaine, Churilov, Leonid, McKendrick, Joseph, Renwick, William, Blombery, Piers, Burgess, Melinda, Nelson, Niles Elizabeth, Fancourt, Tineke, Hawking, Joanne, Lin, Wendi, Scott, Andrew M., Barraclough, Allison, Wight, Joel, Grigg, Andrew, Fong, Chun Yew and Hawkes, Eliza A. (2023). Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study. Leukemia, 37 (5), 1092-1102. doi: 10.1038/s41375-023-01863-7 |
|
2022 Journal Article Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases RegistryBaggio, Diva, Wellard, Cameron, Chung, Eliza, Talaulikar, Dipti, Keane, Colm, Opat, Stephen, Giri, Pratyush, Minson, Adrian, Cheah, Chan Yoon, Armytage, Tasman, Lee, Denise, Chong, Geoffrey, Johnston, Anna, Cochrane, Tara, Waters, Neil, Hamad, Nada, Wood, Erica M. and Hawkes, Eliza A. (2022). Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry. Leukemia & Lymphoma, 64 (3), 621-627. doi: 10.1080/10428194.2022.2157676 |
|
2022 Conference Publication Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin LymphomaJohnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth P., Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash and Timmerman, John (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166846 |
|
2022 Conference Publication Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 TreatmentTimmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Tsoran-Rosenthal, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, West, Rachel Marceau, Pillai, Pallavi, Nahar, Akash and Herrera, Alex F. (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166670 |
|
2022 Journal Article Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases RegistryLymphoma and Related Diseases Registry Investigators, Gandhi, Maher K. and Keane, Colm (2022). Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Medical Research Methodology, 22 (1) 266, 1-10. doi: 10.1186/s12874-022-01728-0 |
|
2022 Conference Publication Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 TreatmentTimmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, Zhang, Hong, Pillai, Pallavi, Nahar, Akash and Herrera, Alex F. (2022). Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment. 12th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22-24 October 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000890800.36906.bb |
|
2022 Conference Publication Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin LymphomaBorchmann, Peter, Johnson, Nathalie A., Lavie, David, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash and Timmerman, John (2022). Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. 12th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22-24 October 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000890812.66186.e8 |
|
2022 Conference Publication Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin LymphomaGunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Bednarska, Karolina, Brosda, Sandra, Zaharia, Andreea, Tsang, Hennes, de Long, Lilia M., Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher K. (2022). Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, 23-25 June 2022, Boston, MA USA. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/2643-3249.lymphoma22-a17 |
|
2022 Journal Article Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma AllianceKeane, Colm, Hamad, Nada, Barraclough, Allison, Lee, Yoo Y., Talaulikar, Dipti, Ku, Matthew, Wight, Joel, Tatarczuch, Maciej, Swain, Fiona and Gregory, Gareth P. (2022). Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 52 (9), 1624-1632. doi: 10.1111/imj.15658 |
